How Does Johnson & Johnson Stock Stack Up Against Its Peers?
Here is how Johnson & Johnson (JNJ) stock stacks up against its peers in size, valuation, growth and margin.
- JNJ’s operating margin of 26.2% is high, higher than most peers though lower than LLY (43.0%).
- JNJ’s revenue growth of 5.1% in the last 12 months is moderate, outpacing MRK, BMY but lagging LLY, ABBV, PFE.
- JNJ gained 21.9% in the past year and trades at a PE of 17.9, outperforming its peers.
As a quick background, Johnson & Johnson provides healthcare products globally, including baby care, pharmaceuticals for inflammatory diseases, and MedTech electrophysiology solutions for cardiovascular treatment.
A single stock can be risky, but there is a huge value to a broader, diversified approach. Quiz time: Over the last 5 years, which index do you think the Trefis High Quality Portfolio outperformed — the S&P 500, the S&P 1500 Equal Weighted, or both? The answer might surprise you. See how our advisory framework helps stack the odds in your favor.
| JNJ | LLY | ABBV | MRK | PFE | BMY | |
|---|---|---|---|---|---|---|
| Market Cap ($ Bil) | 450.0 | 814.3 | 381.7 | 210.5 | 138.1 | 92.8 |
| Revenue ($ Bil) | 92.1 | 53.3 | 58.3 | 63.6 | 63.8 | 48.0 |
| PE Ratio | 17.9 | 59.0 | 101.4 | 12.8 | 12.8 | 15.4 |
| LTM Revenue Growth | 5.1% | 36.8% | 6.1% | 1.8% | 13.5% | 1.3% |
| LTM Operating Margin | 26.2% | 43.0% | 23.5% | 31.2% | 26.1% | 23.8% |
| LTM FCF Margin | 20.3% | -0.1% | 31.3% | 23.1% | 19.5% | 31.9% |
| 12M Market Return | 21.9% | 13.4% | 11.5% | -14.6% | -6.3% | -13.7% |
Why does this matter? JNJ just went down -0.7% in a month – peer comparison puts stock performance, valuation, and financials in context – highlighting whether it is truly outperforming, lagging behind, and above all – can this continue? Read Buy or Sell JNJ Stock to see if Johnson & Johnson is really a falling knife.
Revenue Growth Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| JNJ | 5.1% | 4.3% | 6.5% | 1.6% |
| LLY | 36.8% | 32.0% | 19.6% | 0.8% |
| ABBV | 6.1% | 3.7% | -6.4% | 3.3% |
| MRK | 1.8% | 6.7% | 1.4% | 21.7% |
| PFE | 13.5% | 6.8% | -41.1% | 24.5% |
| BMY | 1.3% | 7.3% | -2.5% | -0.5% |
Operating Margin Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| JNJ | 26.2% | 24.9% | 27.5% | 26.3% |
| LLY | 43.0% | 38.9% | 31.6% | 30.3% |
| ABBV | 23.5% | 21.1% | 24.9% | 32.4% |
| MRK | 31.2% | 31.5% | 4.9% | 30.8% |
| PFE | 26.1% | 23.5% | 7.4% | 37.7% |
| BMY | 23.8% | 12.2% | 18.2% | 19.7% |
PE Ratio Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| JNJ | 17.9 | 24.8 | 11.3 | 25.8 |
| LLY | 59.0 | 65.7 | 100.1 | 52.8 |
| ABBV | 101.4 | 73.5 | 56.3 | 24.2 |
| MRK | 12.8 | 14.7 | 757.8 | 19.3 |
| PFE | 12.8 | 18.7 | 76.7 | 9.2 |
| BMY | 15.4 | -12.8 | 13.2 | 24.2 |
While peer comparison is critical, the Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.